Amgen, Inc.
- Country
- ๐บ๐ธUnited States
- Ownership
- Public
- Established
- 1980-01-01
- Employees
- 26.7K
- Market Cap
- $175.6B
- Website
- http://www.amgen.com
Apremilast Pediatric Study in Children With Active Juvenile Psoriatic Arthritis
- Conditions
- Active Juvenile Psoriatic Arthritis
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-03-18
- Last Posted Date
- 2025-02-26
- Lead Sponsor
- Amgen
- Target Recruit Count
- 60
- Registration Number
- NCT04804553
- Locations
- ๐ฌ๐ง
Nottingham Childrens Hospital, Nottingham, United Kingdom
๐ฎ๐นOspedale Santissima Annunziata, Chieti, Italy
๐ฆ๐นLandeskrankenhaus Bregenz, Bregenz, Austria
Pegloticase and Methotrexate Co-administered in Participants With Uncontrolled Gout Who Previously Failed Pegloticase Monotherapy
- Conditions
- Uncontrolled Gout
- Interventions
- Biological: Pegloticase
- First Posted Date
- 2021-02-26
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- Amgen
- Target Recruit Count
- 11
- Registration Number
- NCT04772313
- Locations
- ๐บ๐ธ
Providence St. John's Health Clinic, Santa Monica, California, United States
๐บ๐ธIRIS Research and Development, LLC, Plantation, Florida, United States
๐บ๐ธBiopharma Informatic, LLC, Houston, Texas, United States
A Study to Investigate Interchangeability of ABP 654 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
- First Posted Date
- 2021-02-21
- Last Posted Date
- 2024-01-11
- Lead Sponsor
- Amgen
- Target Recruit Count
- 494
- Registration Number
- NCT04761627
- Locations
- ๐จ๐ฆ
Enverus Medical Research, Surrey, British Columbia, Canada
๐จ๐ฆGuelph Dermatology Research, Guelph, Ontario, Canada
๐บ๐ธCenter for Clinical Studies, LTD., LLP, Webster, Texas, United States
A Study of AMG 340 in Subjects With Metastatic Castrate-Resistant Prostate Carcinoma
- First Posted Date
- 2021-02-05
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- Amgen
- Target Recruit Count
- 42
- Registration Number
- NCT04740034
- Locations
- ๐บ๐ธ
Icahn School of Medicine at Mount Sinai, New York, New York, United States
๐บ๐ธTennessee Oncology, Nashville, Tennessee, United States
๐บ๐ธUCSF, San Francisco, California, United States
Study of AMG 994 Monotherapy and AMG 994 and AMG 404 Combination Therapy in Participants With Advanced Solid Tumors
- First Posted Date
- 2021-01-27
- Last Posted Date
- 2025-01-06
- Lead Sponsor
- Amgen
- Target Recruit Count
- 11
- Registration Number
- NCT04727554
- Locations
- ๐ฆ๐บ
Linear Clinical Research Limited, Nedlands, Western Australia, Australia
๐บ๐ธSarah Cannon Research Institute, Nashville, Tennessee, United States
๐บ๐ธUniversity of Texas MD Anderson Cancer Center, Houston, Texas, United States
A Study of AMG 757 in Participants With Neuroendocrine Prostate Cancer
- First Posted Date
- 2021-01-11
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- Amgen
- Target Recruit Count
- 41
- Registration Number
- NCT04702737
- Locations
- ๐บ๐ธ
Community Health Network MD Anderson Cancer Center - North, Indianapolis, Indiana, United States
๐ฆ๐บChris OBrien Lifehouse, Camperdown, New South Wales, Australia
๐ฆ๐บPeter MacCallum Cancer Centre, Melbourne, Victoria, Australia
Efficacy and Safety of Efavaleukin Alfa in Subjects With Active Systemic Lupus Erythematosus
- Conditions
- Active Systemic Lupus Erythematosus
- Interventions
- First Posted Date
- 2020-12-23
- Last Posted Date
- 2024-06-28
- Lead Sponsor
- Amgen
- Target Recruit Count
- 168
- Registration Number
- NCT04680637
- Locations
- ๐ซ๐ท
Centre Hospitalier Universitaire de Toulouse - Hopital Rangueil, Toulouse Cedex 9, France
๐ฏ๐ตCenter Hospital of the National Center for Global Health and Medicine, Shinjuku-ku, Tokyo, Japan
๐ฐ๐ทDaegu Catholic Universtiy Medcial Center, Daegu, Korea, Republic of
Expanded Access of Sotorasib
- Conditions
- Non Small-cell Lung CancerLocally Advanced Unresectable NSCLCLocally Advanced Metastatic NSCLC
- First Posted Date
- 2020-12-14
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- Amgen
- Registration Number
- NCT04667234
- Locations
- ๐บ๐ธ
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
๐บ๐ธOncology Hematology Associates, Springfield, Missouri, United States
๐บ๐ธMcFarland Clinic PC, Ames, Iowa, United States
Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC)
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- First Posted Date
- 2020-11-17
- Last Posted Date
- 2024-08-29
- Lead Sponsor
- Amgen
- Target Recruit Count
- 65
- Registration Number
- NCT04631601
- Locations
- ๐บ๐ธ
University of Alabama at Birmingham, Birmingham, Alabama, United States
๐บ๐ธUniversity of California at Irvine Medical Center, Orange, California, United States
๐บ๐ธUniversity of California San Francisco Mission Bay Campus, San Francisco, California, United States
A Study to Investigate ABP 654 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
- First Posted Date
- 2020-10-29
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Amgen
- Target Recruit Count
- 563
- Registration Number
- NCT04607980
- Locations
- ๐จ๐ฆ
Toronto Research Centre - Dermatology, Toronto, Ontario, Canada
๐บ๐ธFirst OC Dermatology, Fountain Valley, California, United States
๐จ๐ฆDermEdge Research Inc., Mississauga, Ontario, Canada